Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Dec;40(12):2743–2748. doi: 10.1128/aac.40.12.2743

Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients.

G Gatti 1, M Merighi 1, J Hossein 1, S Travaini 1, R Casazza 1, M Karlsson 1, M Cruciani 1, D Bassetti 1
PMCID: PMC163614  PMID: 9124833

Abstract

The population pharmacokinetics of dapsone were examined in human immunodeficiency virus-infected patients receiving dapsone at a dosage of 100 mg twice weekly for the prevention of Pneumocystis carinii pneumonia. Nonlinear mixed-effect modeling was used to determine the best pharmacostatistical model for the data. A one-compartment open model with first-order absorption and elimination was used as the structural pharmacokinetic model. Several covariates were tested for their influence on pharmacokinetic parameters. Rifampin was found to increase the values of clearance/bioavailability (CL/F) and volume of distribution/ bioavailability (V/F) by approximately 70%. CL/F and V/F were 1.83 liters/h and 69.6 liters, respectively, for patients not taking rifampin. The effect of rifampin on the pharmacokinetic parameters of dapsone was appreciably less than expected on the basis of studies with healthy volunteers. Increased bilirubin levels were associated with a significant decrease in the absorption rate constant (Ka). However, this finding may be considered clinically irrelevant because the post hoc Bayesian estimates of Ka for patients with high bilirubin levels ( > 1.2 mg/dl) were at the lower bound of the values for patients with normal bilirubin levels. The value of Ka was 0.957 h-1 for a patient with a bilirubin level of 0.7 mg/dl. After inclusion of covariates in the model, the interpatient variability was 35% for CL/F, not significant for V/F, and 85% for Ka. Simulation of plasma concentration-versus-time curves indicated that the administration of 100 mg of dapsone biweekly is associated with sustained dapsone levels in the plasma of the majority of the patients. Dosage adjustments for patients concomitantly treated with rifampin may be necessary.

Full Text

The Full Text of this article is available as a PDF (263.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Backman J. T., Olkkola K. T., Neuvonen P. J. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996 Jan;59(1):7–13. doi: 10.1016/S0009-9236(96)90018-1. [DOI] [PubMed] [Google Scholar]
  2. Balakrishnan, Seshadri P. S. Drug interactions -- the influence of rifampicin and clofazimine on the urinary excretion of DDS. Lepr India. 1981 Jan;53(1):17–22. [PubMed] [Google Scholar]
  3. Blum R. N., Miller L. A., Gaggini L. C., Cohn D. L. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr. 1992;5(4):341–347. [PubMed] [Google Scholar]
  4. Carr A., Gross A. S., Hoskins J. M., Penny R., Cooper D. A. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS. 1994 Mar;8(3):333–337. doi: 10.1097/00002030-199403000-00006. [DOI] [PubMed] [Google Scholar]
  5. Clotet B., Sirera G., Romeu J., Gimeno J. M., Jou A., Condom M. J., Tor J., Foz M. Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis. AIDS. 1991 May;5(5):601–602. [PubMed] [Google Scholar]
  6. Coker R. J., Nieman R., McBride M., Mitchell D. M., Harris J. R., Weber J. N. Co-trimoxazole versus dapsone-pyrimethamine for prevention of Pneumocystis carinii pneumonia. Lancet. 1992 Oct 31;340(8827):1099–1099. doi: 10.1016/0140-6736(92)93120-c. [DOI] [PubMed] [Google Scholar]
  7. Cushion M. T., Stanforth D., Linke M. J., Walzer P. D. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro. Antimicrob Agents Chemother. 1985 Dec;28(6):796–801. doi: 10.1128/aac.28.6.796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Edstein M. D., Rieckmann K. H., Veenendaal J. R. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. Br J Clin Pharmacol. 1990 Aug;30(2):259–265. doi: 10.1111/j.1365-2125.1990.tb03773.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Evans D. A. N-acetyltransferase. Pharmacol Ther. 1989;42(2):157–234. doi: 10.1016/0163-7258(89)90036-3. [DOI] [PubMed] [Google Scholar]
  10. Falloon J., Lavelle J., Ogata-Arakaki D., Byrne A., Graziani A., Morgan A., Amantea M. A., Ownby K., Polis M., Davey R. T., Jr Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia. Antimicrob Agents Chemother. 1994 Jul;38(7):1580–1587. doi: 10.1128/aac.38.7.1580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gatti G., Loy A., Casazza R., Miletich F., Cruciani M., Bassetti D. Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 1995 May;39(5):1101–1106. doi: 10.1128/aac.39.5.1101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gelber R., Peters J. H., Gordon G. R., Glazko A. J., Levy L. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225–238. doi: 10.1002/cpt1971122part1225. [DOI] [PubMed] [Google Scholar]
  13. Girard P. M., Landman R., Gaudebout C., Olivares R., Saimot A. G., Jelazko P., Gaudebout C., Certain A., Boué F., Bouvet E. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N Engl J Med. 1993 May 27;328(21):1514–1520. doi: 10.1056/NEJM199305273282102. [DOI] [PubMed] [Google Scholar]
  14. Hughes W. T., Kennedy W., Dugdale M., Land M. A., Stein D. S., Weems J. J., Jr, Palte S., Lancaster D., Gidan-Kovnar S., Morrison R. E. Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone. Lancet. 1990 Oct 27;336(8722):1066–1066. doi: 10.1016/0140-6736(90)92533-n. [DOI] [PubMed] [Google Scholar]
  15. Kemper C. A., Tucker R. M., Lang O. S., Kessinger J. M., Greene S. I., Deresinski S. C., Stevens D. A. Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. AIDS. 1990 Nov;4(11):1145–1148. doi: 10.1097/00002030-199011000-00015. [DOI] [PubMed] [Google Scholar]
  16. Lee B. L., Medina I., Benowitz N. L., Jacob P., 3rd, Wofsy C. B., Mills J., 5th Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med. 1989 Apr 15;110(8):606–611. doi: 10.7326/0003-4819-110-8-606. [DOI] [PubMed] [Google Scholar]
  17. Lee B. L., Wong D., Benowitz N. L., Sullam P. M. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1993 May;53(5):529–535. doi: 10.1038/clpt.1993.66. [DOI] [PubMed] [Google Scholar]
  18. Mallolas J., Zamora L., Gatell J. M., Miró J. M., Vernet E., Valls M. E., Soriano E., SanMiguel J. G. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS. 1993 Jan;7(1):59–64. [PubMed] [Google Scholar]
  19. Martin M. A., Cox P. H., Beck K., Styer C. M., Beall G. N. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch Intern Med. 1992 Mar;152(3):523–528. [PubMed] [Google Scholar]
  20. May D. G., Arns P. A., Richards W. O., Porter J., Ryder D., Fleming C. M., Wilkinson G. R., Branch R. A. The disposition of dapsone in cirrhosis. Clin Pharmacol Ther. 1992 Jun;51(6):689–700. doi: 10.1038/clpt.1992.81. [DOI] [PubMed] [Google Scholar]
  21. May D. G., Porter J. A., Uetrecht J. P., Wilkinson G. R., Branch R. A. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther. 1990 Dec;48(6):619–627. doi: 10.1038/clpt.1990.204. [DOI] [PubMed] [Google Scholar]
  22. Opravil M., Joos B., Lüthy R. Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antimicrob Agents Chemother. 1994 May;38(5):1197–1199. doi: 10.1128/aac.38.5.1197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Philip P. A., Roberts M. S., Rogers H. J. A rapid method for determination of acetylation phenotype using dapsone. Br J Clin Pharmacol. 1984 Apr;17(4):465–469. doi: 10.1111/j.1365-2125.1984.tb02373.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Podzamczer D., Santín M., Jimenez J., Casanova A., Bolao F., Gudiol G. R. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS. 1993 Apr;7(4):501–506. doi: 10.1097/00002030-199304000-00008. [DOI] [PubMed] [Google Scholar]
  25. Slavin M. A., Hoy J. F., Stewart K., Pettinger M. B., Lucas C. R., Kent S. J. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS. 1992 Oct;6(10):1169–1174. [PubMed] [Google Scholar]
  26. Torres R. A., Barr M., Thorn M., Gregory G., Kiely S., Chanin E., Carlo C., Martin M., Thornton J. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med. 1993 Dec;95(6):573–583. doi: 10.1016/0002-9343(93)90352-p. [DOI] [PubMed] [Google Scholar]
  27. Zuidema J., Hilbers-Modderman E. S., Merkus F. W. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet. 1986 Jul-Aug;11(4):299–315. doi: 10.2165/00003088-198611040-00003. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES